---
title: "Performance evaluation"
url: https://normiq.app/en/regulations/ivdr-art-56
language: en
updated: 2026-09-03
---

# Performance evaluation

IVDR Art. 56

Obligation to demonstrate the scientific validity, analytical performance and clinical performance of the device

- [Official text — IVDR, Article 56](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02017R0746-20250110#art_56)

EUR-Lex, consolidated version of January 10, 2025, at the provision’s anchor.

- Category

  Founding texts

- Market

  European Union

- Applicable classes

  Class A IVD, Class B IVD, Class C IVD, Class D IVD

- Applicable since

  May 26, 2022

## In practice

Three pillars, mandatory for every class: scientific validity of the analyte, analytical performance (trueness, sensitivity, specificity, limits, interference) and clinical performance (diagnostic sensitivity and specificity, predictive values). The performance evaluation plan and report follow Annex XIII Part A and enter the technical documentation. Regulated studies fall under Articles 57 onwards.

## Official sources

<https://eur-lex.europa.eu/eli/reg/2017/746/oj/eng>

## See where this text lands in your roadmap

Normiq places every deadline in your device's roadmap, with the steps that lead to it. Free 7-day trial.

[Start the free trial](https://normiq.app/signup)

## In the same category

- [MDR 2017/745](https://normiq.app/en/regulations/mdr-2017-745)
- [MDR Art. 10](https://normiq.app/en/regulations/mdr-art-10)
- [MDR Art. 52](https://normiq.app/en/regulations/mdr-art-52)
- [MDR Art. 61](https://normiq.app/en/regulations/mdr-art-61)
- [MDR Art. 120](https://normiq.app/en/regulations/mdr-art-120)
- [MDR Art. 29 et 31](https://normiq.app/en/regulations/mdr-art-29-et-31)
- [MDR Art. 27](https://normiq.app/en/regulations/mdr-art-27)
- [MDR Annexe I](https://normiq.app/en/regulations/mdr-annexe-i)
